During the recent session, Pharvaris NV (NASDAQ:PHVS)’s traded shares were 0.28 million, with the beta value of the company hitting -3.10. At the last check today, the stock’s price was $19.87, reflecting an intraday loss of -5.78% or -$1.22. The 52-week high for the PHVS share is $33.00, that puts it down -66.08 from that peak though still a striking 24.51% gain since the share price plummeted to a 52-week low of $15.00. The company’s market capitalization is $1.07B, and the average intraday trading volume over the past 10 days was 0.11 million shares, and the average trade volume was 78.19K shares over the past three months.

Pharvaris NV (PHVS) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.38. PHVS has a Sell rating from 0 analyst(s) out of 4 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 4 recommend a Buy rating for it. 0 analyst(s) has rated the stock Underweight. Company’s earnings per share (EPS) for the current quarter are expected to be -0.67.

Pharvaris NV (NASDAQ:PHVS) trade information

Pharvaris NV (PHVS) registered a -5.78% downside in the last session and has traded in the red over the past 5 sessions. The stock plummet -5.78% in intraday trading to $19.87, hitting a weekly high. The stock’s 5-day price performance is -5.02%, and it has moved by 11.69% in 30 days. Based on these gigs, the overall price performance for the year is 1.64%. The short interest in Pharvaris NV (NASDAQ:PHVS) is 0.18 million shares and it means that shorts have 2.42 day(s) to cover.

The consensus price target of analysts on Wall Street is $38.5, which implies an increase of 48.39% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $27 and $50 respectively. As a result, PHVS is trading at a discount of -151.64% off the target high and -35.88% off the low.

Pharvaris NV (PHVS) estimates and forecasts

Statistics show that Pharvaris NV has underperformed its competitors in share price, compared to the industry in which it operates. Pharvaris NV (PHVS) shares have gone down -20.52% during the last six months, with a year-to-date growth rate less than the industry average at 9.15% against 17.30. Yet analysts are ramping up their growth forecast for the fiscal year 2024. Revenue is predicted to shrink -6.30% this quarter and then jump 7.40% in the quarter after that.

An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -28.27%. While earnings are projected to return 9.90% in 2024, the next five years will return 20.59% per annum.

PHVS Dividends

Pharvaris NV is due to release its next quarterly earnings on 2024-Aug-14. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.

The next largest institutional holding, with 5.21 million shares, is of FMR LLC’s that is approximately 9.6729% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $97.87 million.

Also, the Mutual Funds coming in first place with the largest holdings of Pharvaris NV (PHVS) shares are Fidelity Growth Company Fund and Fidelity Select Portfolios – Health Care . Data provided on Jul 31, 2024 indicates that Fidelity Growth Company Fund owns about 960.32 shares. This amounts to just over 1.84 percent of the company’s overall shares, with a $19.04 million market value. The same data shows that the other fund manager holds slightly less at 740.75, or about 1.42% of the stock, which is worth about $14.69 million.